FUNDAMENTALS · Fundamentals · CN Healthcare

PW Medtech Group (1358) Fundamentals 2026 — P/E 14.6x, Revenue Analysis | SniperIQ

PW Medtech Group (1358) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of HK

.5B, trading at HK
.06 on the HKSE. This SniperIQ fundamentals page covers PW Medtech Group's valuation (P/E 14.6x, P/B 0.4x), profitability (net margin 11.5%), revenue (¥824M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
.5B
P/E (TTM)14.6x
Net Margin11.5%
Revenue (FY25)¥824M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is PW Medtech Group's market cap?

PW Medtech Group (1358) has a market capitalization of approximately HK

.5B, trading at HK
.06 on the HKSE. Market cap moves with the live share price.

What is PW Medtech Group's P/E ratio?

PW Medtech Group's trailing twelve-month P/E ratio is 14.6x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is PW Medtech Group?

PW Medtech Group runs a net profit margin of 11.5%, a gross margin of 49.5%, and an operating margin of 14.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does PW Medtech Group generate?

PW Medtech Group reported revenue of ¥824M for fiscal year 2025, with net income of ¥94M and earnings per share (EPS) of 0.0625. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does PW Medtech Group pay a dividend?

PW Medtech Group offers a trailing dividend yield of about 6.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is PW Medtech Group financially healthy?

PW Medtech Group carries a debt-to-equity ratio of 0.01x and a current ratio of 10.89x, with a market beta of 0.72. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is PW Medtech Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PW Medtech Group (1358) the key facts are: market cap HK

.5B, P/E 14.6x, revenue ¥824M, 52-week range 0.97-1.63. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track PW Medtech Group's full fundamentals live

Get PW Medtech Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Enovis (ENOV) fundamentals · Bicara Therapeutics Inc. Common Stock (BCAX) fundamentals · Monte Rosa Therapeutics (GLUE) fundamentals · Septerna (SEPN) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons